Insider Selling: Gilead Sciences, Inc. (NASDAQ:GILD) Insider Sells 73,333 Shares of Stock
Gilead Sciences, Inc. (NASDAQ:GILD) insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Shares of Gilead Sciences, Inc. (GILD) traded down 1.63% during mid-day trading on Friday, hitting $73.16. The stock had a trading volume of 14,960,574 shares. The stock has a market cap of $95.55 billion, a P/E ratio of 7.95 and a beta of 1.21. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $82.10. The firm has a 50 day moving average price of $70.60 and a 200-day moving average price of $68.59.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping analysts’ consensus estimates of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. Gilead Sciences’s revenue for the quarter was down 8.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.08 earnings per share. On average, equities research analysts forecast that Gilead Sciences, Inc. will post $8.76 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.84%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is 22.58%.
A number of analysts have recently commented on the company. Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Thursday, July 27th. Leerink Swann reiterated a “hold” rating and issued a $74.00 price objective on shares of Gilead Sciences in a research report on Tuesday, July 25th. Cowen and Company reiterated an “outperform” rating and issued a $90.00 price objective on shares of Gilead Sciences in a research report on Thursday, July 27th. BidaskClub raised Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. Finally, J P Morgan Chase & Co set a $85.00 price target on Gilead Sciences and gave the stock an “overweight” rating in a research report on Thursday, July 27th. Eleven equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $80.31.
A number of institutional investors have recently modified their holdings of GILD. Massmutual Trust Co. FSB ADV acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $3,239,000. Rockland Trust Co. increased its position in shares of Gilead Sciences by 16.7% in the first quarter. Rockland Trust Co. now owns 178,245 shares of the biopharmaceutical company’s stock worth $12,106,000 after buying an additional 25,551 shares during the last quarter. Linscomb & Williams Inc. increased its position in shares of Gilead Sciences by 3.0% in the first quarter. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company’s stock worth $358,000 after buying an additional 154 shares during the last quarter. Berkshire Asset Management LLC PA acquired a new position in shares of Gilead Sciences during the first quarter worth about $270,000. Finally, Sigma Planning Corp increased its position in shares of Gilead Sciences by 7.7% in the first quarter. Sigma Planning Corp now owns 40,168 shares of the biopharmaceutical company’s stock worth $2,728,000 after buying an additional 2,889 shares during the last quarter. 73.99% of the stock is owned by institutional investors.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.